The content on this site is intended for healthcare professionals only
Dr Lopes presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements.
For more on these results, watch his interview with ecancer and read our news coverage here.
Slides from this presentation are available here.
Innovative treatments for solid tumours – TTFields as a therapeutic modality
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
